Effect of mineral trioxide aggregate on rat clonal dental pulp cells: expression of cyclooxygenase-2 mRNA and inflammation-related protein via nuclear factor kappa B signaling system.
BACKGROUND
Recently, mineral trioxide aggregate (MTA) has been routinely used for endodontic treatment. It is well-known that MTA induced secondary dentin formation in pulp cavity when it was applied to dentin, whereas its cytotoxicities were unclear. The purpose of this study was to evaluate the effect of MTA on rat clonal dental pulp cells, RPC-C2A.


METHODS
This study was conducted to observe the response of RPC-C2A cells on MTA with reverse-transcriptase polymerase chain reaction, Western blot analysis, and enzyme immunoassay. Data were compared by analysis of variance. Statistical significance was established at P <.01.


RESULTS
MTA significantly caused an up-regulation of cyclooxygenase-2 (COX-2) and inducible form of nitric oxide synthase (iNOS) mRNA expression. Furthermore, MTA caused inhibitory kappa B (IkappaB) phosphorylation and translocation of nuclear factor-kappa B (NF-kappaB) subunits to nucleus. Curucumin, an inhibitor of NF-kappaB activation, suppressed MTA-induced COX-2 and iNOS mRNA expressions. In addition, MTA increased the production of prostaglandin E(2) in comparison with the controls.


CONCLUSIONS
MTA induces inflammation via NF-kappaB signaling system.
Minamikawa
Hajime
H
Department of Pediatric Dentistry, Graduate School of Dental Medicine, Hokkaido University, Sapporo, Japan.
Deyama
Yoshiaki
Y
Nakamura
Kouichi
K
Yoshimura
Yoshitaka
Y
Kaga
Masayuki
M
Suzuki
Kuniaki
K
Yawaka
Yasutaka
Y
D021581:Active Transport, Cell Nucleus / Q000187:drug effects; D017607:Aluminum Compounds / Q000633:toxicity*; D000818:Animals; D017610:Calcium Compounds / Q000633:toxicity*; D002478:Cells, Cultured; D051546:Cyclooxygenase 2 / Q000096:biosynthesis*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D003782:Dental Pulp / Q000187:drug effects* / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism; D004338:Drug Combinations; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D020672:I-kappa B Proteins / Q000737:chemistry; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D010087:Oxides / Q000633:toxicity*; D010766:Phosphorylation; D051381:Rats; D012387:Root Canal Filling Materials / Q000633:toxicity*; D015398:Signal Transduction / Q000187:drug effects; D017640:Silicates / Q000633:toxicity*
D017607:Aluminum Compounds; D017610:Calcium Compounds; D052246:Cyclooxygenase 2 Inhibitors; D004338:Drug Combinations; C083487:I kappa B beta protein; D020672:I-kappa B Proteins; D016328:NF-kappa B; D010087:Oxides; D012387:Root Canal Filling Materials; D017640:Silicates; C086631:mineral trioxide aggregate; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D051546:Cyclooxygenase 2; D015232:Dinoprostone